Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients

Journal of International Medical Research

Volumn 38, Issue 3, 2010, Pages 870-883

  Kristensen, M H ^a   Pedersen, P L ^a   Melsen, G V ^a   Ellehauge, J ^a   Mejer, J ^a  

^a Hospital South   (Denmark)

Author keywords

5 Fluorouracil; Anticancer agents; Colorectal cancer; Dihydropyrimidine dehydrogenase; Genetic variants; Methylenetetrahydrofolate reductase; Thymidylate synthase; Toxicity

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXALIPLATIN; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE HEART INFARCTION; ADULT; AGED; ALOPECIA; ANGINA PECTORIS; ARTICLE; BLOOD DONOR; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG TOLERABILITY; DYSESTHESIA; ESOPHAGITIS; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SKIN TOXICITY; THROMBOCYTOPENIA; TOXICOGENETICS; ADENOCARCINOMA; COLORECTAL NEOPLASMS; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; TOXICITY; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; THYMIDYLATE SYNTHASE;

EID: 77954768678     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800313     Document Type: Article

References (72)

1. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J Clin Oncol 1998; 16: 3537-3541.
2. Heidelberger C, Chaudhuri NK, Danneberg P, et al: Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179: 663-666.
3. Duschinsky R, Pleven E, Heidelberger C: The synthesis of 5-fluoropyrimidines. J Am Chem Soc 1957; 79: 4559.
4. Ezzeldin H, Diasio R: Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004; 4: 181-189.
5. Diasio RB, Johnson MR: Dihydropyrimidine dehydrogenase; its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999; 5: 2672-2673.
6. Tuchman M, Stoeckeler JS, Kiang DT, et al: Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 1985; 313: 245-249.
7. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil- induced toxicity. J Clin Invest 1988; 81: 47-51.
8. Gamelin E, Boisdron-Celle M, Delva R, et al: Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998; 16: 1470-1478.
9. McKendrick J, Coutsouvelis J: Capecitabine: effective oral fluoropyrimidine chemotherapy. Expert Opin Pharmacother 2005; 6: 1231-1239.
10. Ciccolini J, Mercier C, Dahan L, et al: Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine dehydrogenase deficiency. Cancer Chemother Pharmacol 2006; 58: 272-275.
11. Ichikawa W: Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer 2006; 9: 145-155.
12. Ma T, Zhu ZG, Ji YB, et al: Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine. World J Gastroenterol 2004; 10: 172-176.
13. Pullarkat ST, Stoehlmacher J, Ghaderi V: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1: 65-70.
14. Bertino JR, Banerjee D: Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time? Clin Cancer Res 2003; 9: 1235-1239.
15. Lecomte T, Ferraz JM, Zinzindohoue F, et al: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-flurouracil-based chemotherapy. Clin Cancer Res 2004; 10: 5880-5888.
16. Candelaria M, Taja-Chayeb L, Arce-Salinas C, et al: Genetic determinants of cancer efficacy and toxicity: practical considerations and perspectives. Anticancer Drugs 2005; 16: 923-933.
17. Kawakami K, Omura K, Kanchira E, et al: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 1999; 19: 3949-3952.
18. Kawakami K, Watanabe G: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003; 63: 6004-6007.
19. Mandola MV, Stoehlmacher J, Zhang W, et al: A 6 bp polymorphism in thymidylate synthase gene causes message instability and is associated with decreased intratumoural TS mRNA levels. Pharmacogenetics 2004; 14: 319-327.
20. Lenz HJ, Zhang W, Zhahedy S, et al: A 6 base-pair deletion in the 3'UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumours. A possible candidate gene for colorectal cancer risk. Proc Am Assoc Cancer Res 2002; 43: 660 [abstract].
21. Dolnick BJ, Cheng YC: Human thymidylate synthetase. II. Derivatives of pteroylmono- and -polyglutamates as substrates and inhibitors. J Biol Chem 1978; 253: 3563-3567.
22. Radparvar S, Houghton PJ, Houghton JA: Effect of polyglutamylation of 5,10-methylenetetra-hydrofolate on the binding of 5-fluoro-2'-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol 1989; 38: 335-342.
23. Sohn KJ, Croxford R, Yates Z, et al: Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004; 96: 134-144.
24. Cohen V, Panet-Raymond V, Sabbaghian N, et al: Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9: 1611-1615.
25. Etienne MC, Formento JL, Chazal M, et al: Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004; 14: 785-792.
26. Jakobsen A, Nielsen JN, Gyldenkerne N, et al: Thymidylate synthase and methylenetetra-hydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365-1369.
27. Lu JW, Gao CM, Wu JZ, et al: Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-fluorouracil in gastric carcinoma. Ai Zheng 2004; 23: 958-962 [in Chinese].
28. Frosst P, Blom HJ, Milos R: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
29. Toffoli G, Veronesi A, Boiocchi M, et al: MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophoshamide, methotrexate, and fluorouracil (CMF). Ann Oncol 2000; 11: 373-374.
30. Danenberg PV, Danenberg KD: Effect of 5,10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2'-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. Biochemistry 1978; 17: 4018-4024.
31. Heggie GD, Sommadossi JP, Cross DS, et al: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203-2206.
32. Diasio RB: Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology (Williston Park) 2001; 15(1 suppl 2): 21-26.
33. van Kuilenburg AB, Haasjes J, Richel DJ, et al: Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6: 4705-4712.
34. Saif MW, Elfiky A, Diasio R: Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin Colorectal Cancer 2006; 6: 219-223.
35. van Kuilenburg AB, Muller EW, Haasjes J, et al: Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 2001; 7: 1149-1153.
36. Collie-Duguid ES, Etienne MC, Milano G, et al: Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000; 10: 217-223.
37. van Kuilenburg AB, Dobritzsch D, Meinsma R, et al: Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J 2002; 364: 157-163.
38. Vreken P, van Kuilenburg AB, Meinsma R, et al: Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum Genet 1997; 101: 333-338.
39. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
40. Chansky K, Benedetti J, Macdonald JS: Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 2005; 103: 1165-1171.
41. Choi J, Kong K, Mozaffar T, Holcombe RF: Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anticancer Drugs 2006; 17: 103-105.
42. Grothey A: Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003; 30: 5-13.
43. Gamelin L, Boisdron-Celle M, Morel A, et al: Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008; 26: 1188-1189.
44. Rudbeck L, Dissing J: Rapid, simple alkaline extraction of human genomic DNA from whole blood, buccal epithelial cells, semen and forensic stains for PCR. Biotechniques 1998; 25: 588-590.
45. American Joint Committee on Cancer (AJCC): AJCC Cancer Staging Manual (Edge SB, Byrd DR, Compton CC, et al, eds). New York: Springer, 2010 (http://www.cancerstaging.org/staging/index.html).
46. Marsh S, Collie-Duguid ES, Li T, et al: Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999; 58: 310-312.
47. Villafranca E, Okruzhnov Y, Dominguez MA, et al: Polymorphism of repeated sequences in the enhancer region of thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 19: 1779-1786.
48. Etienne MC, Lagrange JL, Dassonville O, et al: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248-2253.
49. Keku T, Millikan R, Worley K, et al: 5,10- Methylenetetrahydrofolate reductase codon 677 and 1298 polymorphisms and colon cancer in African Americans and whites. Cancer Epidemiol Biomarkers Prev 2002; 11: 1611-1621.
50. Mattison LK, Johnson MR, Diasio RB: A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics 2002; 12: 133-144.
51. Gross E, Ullrich T, Seck K, et al: Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat 2003; 22: 498.
52. Seck K, Riemer S, Kates R, et al: Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res 2005; 11: 5886-5892.
53. Ridge SA, Sludden J, Brown O, et al: Dihydropyrimidine dehydrogenase pharmaco-genetics in Caucasian subjects. Br J Clin Pharmacol 1998; 46: 151-156.
54. Yamaguchi K, Arai Y, Kanda Y, et al: Germline mutation of dihydropyrimidine dehydrogenase gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res 2001; 92: 337-342.
55. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-815.
56. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
57. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al: Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996; 77: 441-451.
58. van Kuilenburg AB, Meinsma R, van Gennip AH: Pyrimidine degradation defects and severe 5-fluorouracil toxicity. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1371-1375.
59. Labianca R, Beretta G, Clerici M, et al: Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982; 68: 505-510.
60. Mandola MV, Stoehlmacher J, Muller-Weeks S, et al: A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63: 2898-2904.
61. Capitain O, Boisdron-Celle M, Poirier AL, et al: The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J 2008; 8: 256-267.
62. Sharma R, Hoskins JM, Rivory LP, et al: Thymidylate synthase and methylenetetra-hydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 2008; 14: 817-825.
63. Chen J, Hunter DJ, Stampfer MJ, et al: Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 958-962.
64. van Kuilenburg AB, Vreken P, Riva D, et al: Clinical and biochemical abnormalities in a patient with dihydropyrimidine dehydrogenase deficiency due to homozygosity for the C29R mutation. J Inherit Metab Dis 1999; 22: 191-192.
65. Morel A, Boisdron-Celle M, Fey L, et al: Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem 2007; 40: 11-17.
66. Van Kuilenburg AB, Van Lenthe H, Van Gennip AH: Radiochemical assay for determination of dihydropyrimidinase activity using reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999; 729: 307-314
67. Prado CM, Baracos VE, McCargar LJ, et al: Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007; 13: 3264-3268.
68. Sloan JA, Goldberg RM, Sargent DJ, et al: Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002; 20: 1491-1498.
69. Colhoun HM, McKeigue PM, Davey Smith G: Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361: 865-872.
70. Soong R, Diasio RB: Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics 2005; 6: 835-847.
71. Volk J, Reinke F, van Kuilenburg AB, et al: Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. Ann Oncol 2001; 12: 569-571.
72. Blasco H, Boisdron-Celle M, Bougnoux P, et al: A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient. Br J Clin Pharmacol 2008; 65: 966-970.